DE69619526D1 - Fgf9 als spezifischer ligand für fgfr3 - Google Patents
Fgf9 als spezifischer ligand für fgfr3Info
- Publication number
- DE69619526D1 DE69619526D1 DE69619526T DE69619526T DE69619526D1 DE 69619526 D1 DE69619526 D1 DE 69619526D1 DE 69619526 T DE69619526 T DE 69619526T DE 69619526 T DE69619526 T DE 69619526T DE 69619526 D1 DE69619526 D1 DE 69619526D1
- Authority
- DE
- Germany
- Prior art keywords
- fgfr3
- bone
- progenitor cells
- skeletal progenitor
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13795P | 1995-06-12 | 1995-06-12 | |
PCT/IL1996/000011 WO1996041523A1 (en) | 1995-06-12 | 1996-06-12 | Fgf9 as a specific ligand for fgfr3 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69619526D1 true DE69619526D1 (de) | 2002-04-04 |
DE69619526T2 DE69619526T2 (de) | 2002-10-31 |
Family
ID=21690089
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69619526T Expired - Lifetime DE69619526T2 (de) | 1995-06-12 | 1996-06-12 | Fgf9 als spezifischer ligand für fgfr3 |
DE69624239T Expired - Fee Related DE69624239T2 (de) | 1995-06-12 | 1996-06-12 | Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69624239T Expired - Fee Related DE69624239T2 (de) | 1995-06-12 | 1996-06-12 | Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts |
Country Status (12)
Country | Link |
---|---|
US (2) | US6447783B1 (de) |
EP (3) | EP0836380B1 (de) |
JP (3) | JPH11507828A (de) |
CN (1) | CN1195982A (de) |
AT (2) | ATE213590T1 (de) |
AU (2) | AU715996B2 (de) |
CA (2) | CA2224229A1 (de) |
DE (2) | DE69619526T2 (de) |
DK (2) | DK0833620T3 (de) |
ES (2) | ES2173289T3 (de) |
IL (2) | IL122473A (de) |
WO (2) | WO1996041620A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8083745B2 (en) | 2001-05-25 | 2011-12-27 | Conformis, Inc. | Surgical tools for arthroplasty |
US8234097B2 (en) | 2001-05-25 | 2012-07-31 | Conformis, Inc. | Automated systems for manufacturing patient-specific orthopedic implants and instrumentation |
US8480754B2 (en) | 2001-05-25 | 2013-07-09 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US7534263B2 (en) | 2001-05-25 | 2009-05-19 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
US7799077B2 (en) | 2002-10-07 | 2010-09-21 | Conformis, Inc. | Minimally invasive joint implant with 3-dimensional geometry matching the articular surfaces |
US7618451B2 (en) | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US8771365B2 (en) | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US6136040A (en) * | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
US7184814B2 (en) | 1998-09-14 | 2007-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
US7239908B1 (en) | 1998-09-14 | 2007-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
AU772012B2 (en) | 1998-09-14 | 2004-04-08 | Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US20020058036A1 (en) * | 1999-07-27 | 2002-05-16 | Michael Jeffers | Novel fibroblast growth factor and nucleic acids encoding same |
WO2001024833A2 (en) | 1999-10-06 | 2001-04-12 | Tigenix N.V. | In vivo assay for testing the phenotypic stability |
US7482114B2 (en) | 1999-10-06 | 2009-01-27 | Tigenix N.V. | In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation |
CA2386506C (en) | 1999-10-06 | 2012-02-21 | Tigenix N.V. | Isolation of precursor cells and their use for tissue repair |
AU2001239765A1 (en) * | 2000-02-14 | 2001-08-27 | Smith Kline Beecham Corporation | Novel compounds |
WO2001068854A2 (en) * | 2000-03-13 | 2001-09-20 | Amgen, Inc. | Fibroblast growth factor-like molecules and uses thereof |
WO2002022014A1 (en) | 2000-09-14 | 2002-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
EP1364066A2 (de) * | 2001-02-02 | 2003-11-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur identifizierung funktioneller nukleinsäuren |
CA2447694A1 (en) | 2001-05-25 | 2002-12-05 | Imaging Therapeutics, Inc. | Methods and compositions for articular resurfacing |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8439926B2 (en) | 2001-05-25 | 2013-05-14 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2003076467A1 (en) * | 2002-03-14 | 2003-09-18 | Yeda Research And Development Co. Ltd. | Compositions and methods for inducing and regulating bone formation |
WO2004022095A1 (en) * | 2002-09-04 | 2004-03-18 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
AU2003290757A1 (en) | 2002-11-07 | 2004-06-03 | Conformis, Inc. | Methods for determing meniscal size and shape and for devising treatment |
AU2011211453B2 (en) * | 2004-06-21 | 2015-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
CA2571243A1 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US20080260694A1 (en) * | 2004-09-24 | 2008-10-23 | Angioblast Systems, Inc. | Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof |
US7391676B2 (en) * | 2004-12-22 | 2008-06-24 | Asml Netherlands B.V. | Ultrasonic distance sensors |
US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
US20070049739A1 (en) * | 2005-08-30 | 2007-03-01 | Biomet Manufacturing Corp. | Method and system for extracting blood-derived growth factors |
TWI584796B (zh) | 2006-02-06 | 2017-06-01 | 康福美斯公司 | 患者可選擇式關節置換術裝置及外科工具 |
US8623026B2 (en) | 2006-02-06 | 2014-01-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
KR101503939B1 (ko) * | 2007-01-23 | 2015-03-18 | 고리츠다이가쿠호진 요코하마시리츠다이가쿠 | 연골 세포 조제 방법 |
EP2591756A1 (de) | 2007-02-14 | 2013-05-15 | Conformis, Inc. | Implantat und Herstellungsverfahren |
WO2009111626A2 (en) | 2008-03-05 | 2009-09-11 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
AU2009246474B2 (en) | 2008-05-12 | 2015-04-16 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8808303B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US8808297B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
EP2679600A1 (de) | 2009-03-25 | 2014-01-01 | Genentech, Inc. | Anti-FGFR3-Antikörper und Verwendungsverfahren dafür |
BRPI1014917A2 (pt) | 2009-04-16 | 2016-04-19 | Conformis Inc | "dispositivos de artroplastia de junta específica para páciente para reparo de ligamento" |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
CA2782137A1 (en) | 2009-12-11 | 2011-06-16 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
WO2012112694A2 (en) | 2011-02-15 | 2012-08-23 | Conformis, Inc. | Medeling, analyzing and using anatomical data for patient-adapted implants. designs, tools and surgical procedures |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
CA2898415A1 (en) | 2013-01-16 | 2014-07-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
KR20150124941A (ko) | 2013-03-10 | 2015-11-06 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 골 계통 질환 치료약 및 그 용도 |
PT3481859T (pt) | 2016-07-07 | 2022-05-23 | Pfizer | Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos |
JP2020015733A (ja) * | 2019-08-19 | 2020-01-30 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5270197A (en) * | 1990-12-20 | 1993-12-14 | The Children's Medical Center Corporation | Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor |
JP3385040B2 (ja) * | 1991-02-14 | 2003-03-10 | 武田薬品工業株式会社 | グリア活性化因子およびその製造法 |
EP0608546A3 (en) * | 1992-12-22 | 1995-09-27 | Takeda Chemical Industries Ltd | Glia activating factor (gaf), antibodies against it and their uses. |
AU6446194A (en) * | 1993-03-17 | 1994-10-11 | Whittier Institute For Diabetes And Endocrinology, The | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
-
1996
- 1996-06-12 JP JP9502870A patent/JPH11507828A/ja not_active Ceased
- 1996-06-12 DE DE69619526T patent/DE69619526T2/de not_active Expired - Lifetime
- 1996-06-12 JP JP50286997A patent/JP3673281B2/ja not_active Expired - Lifetime
- 1996-06-12 AT AT96917641T patent/ATE213590T1/de not_active IP Right Cessation
- 1996-06-12 IL IL12247396A patent/IL122473A/xx not_active IP Right Cessation
- 1996-06-12 EP EP96917641A patent/EP0836380B1/de not_active Expired - Lifetime
- 1996-06-12 ES ES96917641T patent/ES2173289T3/es not_active Expired - Lifetime
- 1996-06-12 AU AU60144/96A patent/AU715996B2/en not_active Ceased
- 1996-06-12 WO PCT/IL1996/000010 patent/WO1996041620A1/en active IP Right Grant
- 1996-06-12 AU AU60145/96A patent/AU721773B2/en not_active Ceased
- 1996-06-12 EP EP02022340A patent/EP1342476A3/de not_active Withdrawn
- 1996-06-12 DE DE69624239T patent/DE69624239T2/de not_active Expired - Fee Related
- 1996-06-12 US US08/981,030 patent/US6447783B1/en not_active Expired - Lifetime
- 1996-06-12 IL IL12247296A patent/IL122472A/xx not_active IP Right Cessation
- 1996-06-12 AT AT96917640T patent/ATE225652T1/de not_active IP Right Cessation
- 1996-06-12 WO PCT/IL1996/000011 patent/WO1996041523A1/en active IP Right Grant
- 1996-06-12 DK DK96917640T patent/DK0833620T3/da active
- 1996-06-12 DK DK96917641T patent/DK0836380T3/da active
- 1996-06-12 CA CA002224229A patent/CA2224229A1/en not_active Abandoned
- 1996-06-12 CA CA2223701A patent/CA2223701C/en not_active Expired - Lifetime
- 1996-06-12 EP EP96917640A patent/EP0833620B1/de not_active Expired - Lifetime
- 1996-06-12 ES ES96917640T patent/ES2183957T3/es not_active Expired - Lifetime
- 1996-06-12 CN CN96194719A patent/CN1195982A/zh active Pending
-
2002
- 2002-08-02 US US10/212,357 patent/US20020193309A1/en not_active Abandoned
-
2004
- 2004-06-29 JP JP2004192332A patent/JP2004305221A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69619526T2 (de) | Fgf9 als spezifischer ligand für fgfr3 | |
DE69628290D1 (de) | Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle | |
TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
ATE156365T1 (de) | Osteogenische wachstumsfaktoren zur abgabe an zielorgan | |
DE69632401D1 (de) | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung | |
BR0313197A (pt) | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico | |
BR0214217A (pt) | Aumento de função de órgão | |
TR200101793T2 (tr) | CCR5 modülatörleri olarak azabisikloalkanlar | |
HK1033582A1 (en) | Antibodies to death receptor 4 (dr4) and uses thereof | |
DE69625518T2 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
IL146448A0 (en) | Dr4 antibodies and uses thereof | |
IL137581A (en) | Pharmaceutical compositions comprising keratinocyte growth factor products and a non-aqueous carrier | |
GEP20033081B (en) | Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas | |
DK1007566T3 (da) | Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf | |
WO1999051186A3 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
DE69714775D1 (de) | Verfahren zur Tötung von Zielzellen in geernteten Zellpopulationen mit Hilfe von zwei Immunotoxinen | |
DE69737455D1 (de) | Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben | |
CA2069638A1 (en) | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands | |
PL361732A1 (en) | Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy | |
PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
ATE106883T1 (de) | Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten. |